• Elobixibat Hydrate: Transforming Bile Acid Transport in GI a

  2026-07-27

  This thought-leadership article examines the mechanistic depth, translational promise, and strategic future of Elobixibat hydrate as a selective ileal bile acid transporter inhibitor. Integrating clinical validation, competitive perspectives, and emerging research workflows, it provides translational investigators with a roadmap for leveraging Elobixibat hydrate in chronic idiopathic constipation, bowel preparation, and metabolic dysfunction studies. With a critical eye on maturity, limitations, and outlook, this piece establishes new scientific territory beyond standard product summaries.

• IDH2 Regulates TNBC Proliferation via Ferroptosis Suppressio

  2026-07-26

  This study demonstrates that isocitrate dehydrogenase 2 (IDH2) is highly expressed in triple-negative breast cancer (TNBC) and acts as a critical negative regulator of ferroptosis, thereby promoting tumor cell proliferation. Integrating multi-level validation, the research provides mechanistic insight into the metabolic vulnerabilities of TNBC and highlights ferroptosis as a promising therapeutic target.

• Ziprasidone Augmentation in Anxious Depression: Efficacy Ins

  2026-07-25

  This article discusses the nuanced findings from a randomized controlled trial that evaluated ziprasidone augmentation in patients with major depressive disorder, with a focus on those presenting with anxious depression. The study provides important evidence regarding the differential impact of ziprasidone HCl on anxiety and depressive symptoms, informing future directions for both clinical and translational research.

• GLP-1 (9-36) Amide: Unraveling Receptor Antagonism in Metabo

  2026-07-24

  Explore the advanced role of GLP-1 (9-36) amide as a glucagon-like peptide-1 receptor antagonist in metabolic regulation studies. This in-depth article provides scientific insights and experimental guidance beyond current resources.

• L-NAME Hydrochloride: Illuminating NO Pathways in Renal & Va

  2026-07-24

  Explore how L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) shapes mechanistic insight into nitric oxide signaling, apoptosis, and inflammation in renal and vascular models. This article uniquely bridges protocol guidance with translational findings from recent FXR-KLF11 pathway research.

• Concanamycin A: V-type H+-ATPase Inhibitor in Cancer Researc

  2026-07-23

  Concanamycin A stands out as a gold-standard V-type H+-ATPase inhibitor, enabling precise interrogation of endosomal acidification and apoptosis in cancer biology. This article details practical protocols, advanced use-cases, and troubleshooting strategies to maximize experimental reliability with APExBIO’s Concanamycin A.

• Angiotensin II in Vascular Remodeling: Protocols & Innovatio

  2026-07-23

  Angiotensin II, the endogenous octapeptide Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, is indispensable for modeling hypertension and vascular injury in both cell and animal systems. This article delivers advanced, evidence-backed workflows, protocol refinements, and troubleshooting strategies for maximizing reproducibility and insight in cardiovascular and renal research using APExBIO’s Angiotensin II.

• Artesunate (SKU B3662): Reliable Strategies for In Vitro Can

  2026-07-22

  This article addresses practical challenges in cell viability and cytotoxicity assays, demonstrating how Artesunate (SKU B3662) from APExBIO offers reproducibility, high purity, and mechanistic depth for cancer biology research. Scenario-driven insights and protocol guidance help scientists optimize workflows and interpret data with confidence.

• CFDA SE Cell Tracer Kit: Practical Guide for Stable Cell Tra

  2026-07-22

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit addresses the need for robust, long-term cell labeling in cell lineage tracing and proliferation studies. It is not intended for workflows requiring reversible or short-term cell marking and is best suited for applications demanding persistent, covalent labeling with minimal cytotoxicity.

• Sulfo-Cy3 Azide: Advanced Bioconjugation Reagent for Click C

  2026-07-21

  Sulfo-Cy3 azide transforms bioconjugation workflows with unmatched water solubility and photostability, enabling high-fidelity fluorescence labeling even in complex neural tissues. This guide unpacks optimized experimental setups, troubleshooting strategies, and the direct impact on neurodevelopmental research.

• MOG (35-55) Peptide: Precision in Autoimmune Encephalomyelit

  2026-07-21

  Harness the translational power of the MOG (35-55) myelin oligodendrocyte glycoprotein peptide for experimental autoimmune encephalomyelitis. This guide details advanced protocols, troubleshooting, and data-driven insights, integrating the latest mechanistic breakthroughs to elevate multiple sclerosis research models.

• CX-5461: Mechanistic Advances and Translational Insights for

  2026-07-20

  Explore the innovative mechanisms and translational implications of CX-5461, a leading RNA polymerase I inhibitor. This article offers a deeper scientific analysis and practical guidance for cancer research, distinguishing itself from protocol-focused guides.

• Quercetin Modulates Hippo Pathway for Cataract Protection

  2026-07-20

  This study elucidates how quercetin mitigates cataract pathology by suppressing the Hippo signaling pathway, leading to enhanced lens epithelial cell survival and reduced oxidative damage. The findings highlight pathway modulation as a promising strategy for non-surgical cataract intervention.

• Fenofibrate as a PPARα Agonist: Workflows for Liver & Cancer

  2026-07-19

  Fenofibrate, a potent PPARα agonist from APExBIO, empowers researchers to dissect lipid metabolism and cancer pathways with precision. Learn how to optimize experimental design, troubleshoot solubility and cytotoxicity issues, and translate reference study insights into robust in vitro and in vivo workflows.

• CRISPR/Cas9 Disrupts ABCB1 to Reverse Tumor Drug Resistance

  2026-07-18

  The 2016 study demonstrates targeted disruption of the ABCB1 gene via CRISPR/Cas9 genome editing, leading to enhanced sensitivity of multidrug-resistant (MDR) cancer cells to chemotherapeutics. These findings highlight the mechanistic potential of CRISPR-based interventions in overcoming MDR, a central barrier in effective cancer therapy.

451 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page